Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Review Article

Biologics in Inflammatory Immune-mediated Systemic Diseases

Author(s): Gianluca Moroncini*, Giovanni Calogera, Devis Benfaremo and Armando Gabrielli

Volume 18, Issue 12, 2017

Page: [1008 - 1016] Pages: 9

DOI: 10.2174/1389201019666171226152448

Price: $65

Abstract

Background: The use of biologic agents in systemic immune-mediated diseases has dramatically increased in recent years, replacing conventional immunosuppressive strategies that are characterized by unspecific mechanisms of action and burdened with serious adverse effects. Biologic drugs have selective action towards specific targets, with considerable steroid-sparing effect. They are used nowadays to induce remission or treat specific organ involvements in systemic autoimmune diseases.

Conclusion: In this review, we will discuss the scientific evidence supporting the use of biologics in these diseases, with a particular emphasis on their efficacy and safety profile compared to the conventional drugs.

Keywords: ANCA-associated vasculitis, Behcet Disease, belimumab, rituximab, Systemic Lupus Erythematosus (SLE), Systemic Sclerosis (SSc), TNF-inhibitors, tocilizumab.

Next »

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy